SCHEMBL6389222

SCHEMBL6389222

O=C1Nc2cc(Cl)ccc2/C1=C/c1cc2ccccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIRT1 Q96EB6 1/20 0.53
▸ MAP4K1 Q92918 3/20 0.51
▸ PDGFRB P09619 4/20 0.49
▸ LRRK2 Q5S007 1/20 0.49
▸ TUBB4A P04350 2/20 0.48
▸ TUBB P07437 2/20 0.48
▸ TUBA3C P0DPH7 2/20 0.48
▸ TUBA1B P68363 2/20 0.48
▸ TUBA4A P68366 2/20 0.48
▸ TUBB4B P68371 2/20 0.48
▸ TUBB3 Q13509 2/20 0.48
▸ TUBB2A Q13885 2/20 0.48
▸ TUBB8 Q3ZCM7 2/20 0.48
▸ TUBA3E Q6PEY2 2/20 0.48
▸ TUBA1A Q71U36 2/20 0.48
▸ TUBA1C Q9BQE3 2/20 0.48
▸ TUBB6 Q9BUF5 2/20 0.48
▸ TUBB2B Q9BVA1 2/20 0.48
▸ TUBB1 Q9H4B7 2/20 0.48
▸ CES1 P23141 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6389227 1.00 SIRT1 (0.53) SIRT1MAP4K1PDGFRBLRRK2TUBB4A
SCHEMBL6389287 0.90 LRRK2 (0.62) SIRT1MAP4K1PDGFRBLRRK2
SCHEMBL6389284 0.90 LRRK2 (0.62) SIRT1MAP4K1PDGFRBLRRK2
SCHEMBL1538367 0.85 KDR (0.59) SIRT1MAP4K1PDGFRBLRRK2CDK1
SCHEMBL2768013 0.85 KDR (0.59) SIRT1MAP4K1PDGFRBLRRK2CDK1
SCHEMBL6389451 0.78 KDR (0.58) SIRT1MAP4K1PDGFRBCDK1CCNB1
SCHEMBL6390271 0.78 RET (0.62) SIRT1MAP4K1PDGFRBKDRFLT3
SCHEMBL6389448 0.78 KDR (0.58) SIRT1MAP4K1PDGFRBCDK1CCNB1
SCHEMBL6390272 0.78 RET (0.62) SIRT1MAP4K1PDGFRBKDRFLT3
SCHEMBL1021460 0.77 LRRK2 (0.78) PDGFRBLRRK2TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. 2004-02-05 — — US claimed
US-6680335-B2 FOR THERAPY AND PROPHYLAXIS OF CANCER, HYPERTENSION, DEPRESSION, GENERALIZED ANXIETY DISORDER, PHOBIAS, POST-TRAUMATIC STRESS SYNDROME, AVOIDANT PERSONALITY DISORDER, SEXUAL DYSFUNCTION, EATING DISORDERS, OBESITY SUGEN, INC. 2004-01-20 — — US claimed
US-20020183364-A1 Methods of modulating protein tyrosine kinase function with substituted indolinone compounds SUGEN, INC. 2002-12-05 — — US claimed
WO-2000008202-A9 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN INC (US) 2000-07-27 — — WO claimed
WO-2000008202-A2 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN, INC. (US) 2000-02-17 — — WO claimed
US-6878733-B1 Formulations for pharmaceutical agents ionizable as free acids or free bases SUGEN, INC. (US) 2005-04-12 — — US disclosed
US-6855730-B2 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. (US) 2005-02-15 — — US disclosed
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase SUGEN, INC. 2004-02-05 — — US disclosed
US-6680335-B2 FOR THERAPY AND PROPHYLAXIS OF CANCER, HYPERTENSION, DEPRESSION, GENERALIZED ANXIETY DISORDER, PHOBIAS, POST-TRAUMATIC STRESS SYNDROME, AVOIDANT PERSONALITY DISORDER, SEXUAL DYSFUNCTION, EATING DISORDERS, OBESITY SUGEN, INC. 2004-01-20 — — US disclosed
US-6531502-B1 Antitumor SUGEN, INC. 2003-03-11 — — US disclosed
US-20020183364-A1 Methods of modulating protein tyrosine kinase function with substituted indolinone compounds SUGEN, INC. 2002-12-05 — — US disclosed
EP-1233943-A2 IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS Sugen, Inc. (US) 2002-08-28 — — EP disclosed
WO-2001037820-A2 IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS SUGEN, INC. (US) 2001-05-31 — — WO disclosed
WO-2000008202-A9 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN INC (US) 2000-07-27 — — WO disclosed
WO-2000008202-A2 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE SUGEN, INC. (US) 2000-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024010-A1 3-methylidenyl-2-indolinone modulators of protein kinase DMPK, MAP4K3, MAP3K20 SIRT1 1404/4885MAP4K1 10/4885PDGFRB 1860/4885
US-20020183364-A1 Methods of modulating protein tyrosine kinase function with substituted indolinone compounds PNCK, CAMK4, CAMK1 SIRT1 2432/4885MAP4K1 36/4885PDGFRB 727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback